Vivani Medical, Inc. filings document a clinical-stage company with Nasdaq-listed common stock and development activities in NanoPortal™ drug implants and Cortigent neurostimulation devices. Recent Form 8-K reports cover operating results, Regulation FD corporate presentations, material definitive agreements, registered direct offerings and private placements that affect common-stock capital structure.
Proxy materials disclose board elections, executive compensation, equity awards, shareholder voting procedures and other governance matters. The filing record also includes formal disclosures tied to clinical and business updates for Vivani’s semaglutide implant candidates and corporate-structure matters involving its wholly owned Cortigent subsidiary, including the Orion® Visual Cortical Prosthesis System.
Vivani Medical, Inc. disclosed that a director and 10% owner purchased common stock in two private sale transactions. One transaction covered 1,473,214 shares at $1.12 per share under a Share Purchase Agreement dated as of March 26, 2025, with gross proceeds of $1,649,999.68. A second transaction covered 264,551 shares at $1.26 per share under a Share Purchase Agreement dated as of August 11, 2025, with gross proceeds of $333,334.26, in each case priced at the last reported Nasdaq sale price on the day before the agreement date.
Following these purchases, the reporting person beneficially owns 29,625,544 shares of Vivani common stock held directly and through several trusts and investment entities, and Gregg Williams has voting and dispositive power over all of these shares.
Vivani Medical, Inc. insider activity: A reporting person who is both a director and 10% owner of VANI disclosed two private purchases of Vivani Medical common stock dated 11/15/2025. One transaction involved buying 1,473,214 shares at $1.12 per share under a Share Purchase Agreement dated March 26, 2025, with gross proceeds of $1,649,999.68. A second transaction involved buying 264,550 shares at $1.26 per share under a Share Purchase Agreement dated August 11, 2025, with gross proceeds of $333,333.00. After these transactions, the reporting person is shown as beneficially owning 27,887,779 shares of Vivani common stock through a combination of direct holdings, family trusts, and related entities over which Gregg Williams has voting and dispositive power.
Vivani Medical (VANI) filed its Q3 2025 10-Q, reporting continued operating investment as it advances subdermal GLP-1 implant programs. Cash and cash equivalents were $2.6 million at September 30, 2025, down from $18.4 million at year-end, with total assets of $25.0 million and stockholders’ equity of $1.3 million. Net loss was $6.5 million for the quarter and $20.0 million year-to-date, driven by R&D and G&A expenses.
The company highlighted clinical and portfolio progress: LIBERATE-1, the first-in-human study of its NanoPortal technology, met primary objectives with a positive safety and tolerability profile, informing plans to prioritize NPM-139 (semaglutide implant). Vivani outlined plans to initiate a Phase 1 study for NPM-139 in the first half of 2026, pending regulatory clearance. To support operations, Vivani entered equity purchase agreements expected to bring $18.6 million between September 30, 2025 and July 15, 2026, and subsequently raised approximately $6.0 million in a private placement and $9.7 million gross in a registered direct offering in October. Shares outstanding were 72,952,235 as of November 12, 2025.
Vivani Medical, Inc. furnished an 8-K announcing a business update and third quarter 2025 financial results via a press release, and provided a corporate slide presentation. The materials were furnished under Items 2.02 and 7.01 on November 13, 2025 and are available as Exhibits 99.1 (press release) and 99.2 (slides).
The company noted these materials are not deemed “filed” under the Exchange Act. Vivani also posted the current slide deck to the Investors section of its website.
Vivani Medical (VANI) director and 10% owner Gregg G. Williams reported purchasing 3,703,703 shares of common stock on 10/27/2025 at $1.62 per share in a private sale transaction under a Share Purchase Agreement dated 10/26/2025. The transaction totaled $5,999,998.86.
Following the trade, Williams beneficially owned 26,150,015 shares, comprising 4,799,200 held directly and 21,350,815 held indirectly.
Vivani Medical (VANI) secured new capital through two equity transactions. The company completed a private placement of 3,703,703 common shares at $1.62 per share, generating approximately $6.0 million in gross proceeds. No warrants, discounts, or placement fees were involved.
Concurrently, Vivani entered a registered direct offering for 6,000,000 common shares, with gross proceeds of approximately $9.7 million, before a 7.0% placement fee and up to $125,000 of reimbursable expenses paid to ThinkEquity. Directors and officers agreed to 60-day lock-ups from the closing of the registered offering. The registered sale is being made under the company’s effective Form S-3 shelf via a prospectus and prospectus supplement.
Vivani Medical, Inc. launched a registered direct offering of 6,000,000 shares of common stock at $1.62 per share. The company expects gross proceeds of $9,720,000, placement agent fees of 7.0%, and estimates net proceeds of approximately $8.7 million from this offering, with closing expected on or about October 28, 2025 subject to customary conditions.
Concurrently, an entity affiliated with director Gregg Williams agreed to purchase 3,703,703 shares in a separate private placement at the same price, generating an estimated additional $5.9 million in net proceeds; this sale is not part of the registered offering and carries no underwriting discounts or commissions. Combined net proceeds are approximately $14.7 million. Shares outstanding are expected to be 72,952,235 after the offering and concurrent private placement. Proceeds will fund research and clinical development, working capital, capital expenditures, and general corporate purposes, with management indicating funding into 2027.
Vivani Medical (VANI) insider filed a Form 4 reporting open-market style private purchases. On 10/15/2025, the reporting person, a Director and 10% Owner, acquired 1,473,214 shares at $1.12 per share pursuant to a Share Purchase Agreement dated March 26, 2025, and 264,550 shares at $1.26 per share pursuant to a Share Purchase Agreement dated August 11, 2025.
Following these transactions, beneficial ownership stood at 17,647,112 shares held indirectly and 4,799,200 shares held directly, for a combined 22,446,312 shares with voting and dispositive power over all such shares.
Vivani Medical, Inc. reported that it has temporarily withdrawn the previously announced October 8, 2025 record date for the planned spin-off of its wholly owned subsidiary, Cortigent, Inc. The change was announced on October 3, 2025 and is attributed to delays arising from the current shutdown of the U.S. federal government.
Cortigent is developing brain implant devices using neuromodulation technology, and the spin-off remains proposed, but the timing of determining which shareholders would be eligible to receive shares is now on hold until a new record date is set.
Gregg Williams, a director and reported 10% owner of Vivani Medical, Inc. (VANI), purchased shares in two private transactions during 2025. On 03/26/2025 he bought 1,473,215 shares at $1.12 per share (gross $1,650,000.80). On 08/11/2025 he bought 595,238 shares at $1.26 per share (gross $749,999.88). Following the reported transactions dated 09/15/2025, the filing shows beneficial ownership totaling 20,708,548 shares, with a detailed breakdown across trusts and entities for which he has voting and dispositive power. The Form 4 was signed by an attorney-in-fact on 09/17/2025.